Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Ginderachter, Laura, Cox, Tony, Drijkoningen, Ria, Achten, Ruth, Joosens, Eric, Maes, Annelies, Theunissen, Koen, Mebis, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: January, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573799/
https://www.ncbi.nlm.nih.gov/pubmed/23466981
http://dx.doi.org/10.1159/000346614
Descripción
Sumario:Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.

Ejemplares similares